Vivus diet pill gets thumbs-down in Europe

European regulators aren't sold on the new Vivus weight loss pill. The Committee for Medicinal Products for Human use nixed Vivus' ($VVUS) application for approval, citing worries about Qsiva's safety and probable off-label use. The committee's rejection means Qsiva's European debut will be delayed for about 6 months--if not indefinitely. Sold as Qsymia in the U.S., the Vivus drug launched recently, accompanied by a barrage of media coverage. Story

Add new comment

Images
More information
  • Files must be less than 2 MB.
  • Allowed file types: png gif jpg jpeg.
Documents
More information
  • Files must be less than 2 MB.
  • Allowed file types: zip rar.